Recursion Pharmaceuticals, Inc. RXRX
At closeNov 13, 2026, 7:56 PM EST
After hours · Nov 13, 7:56 PM ET
- YTD
- -22.13%
- 1 year
- -26.44%
- Market cap
- 1.99B
- Revenue (ttm)
- 68.23M
- EPS (ttm)
- -0.86
- Shares out
- 622.76M
- Forward P/E
- -3.86
- YTD return
- -22.13%
- 1-year return
- -26.44%
- Volume
- 16.72M
- Avg volume
- 23.08M
- Open
- 3.33
- Previous close
- 3.33
- Day's range
- 3.16 – 3.34
- 52-week range
- 2.84 – 4.96
- Beta
- 1.15
- Analysts
- Buy
- Price target
- 7.32 (+129.7%)
- Earnings date
- Feb 24, 2027
5D -0.34 (-9.63%)
Key statistics
- Enterprise value
- 1.60B
- PEG ratio
- 0.00
- Price / sales
- 29.10
- Price / book
- 1.97
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 258.50%
- Free cash flow
- -203.12M
- Total cash
- 549.85M
- Total debt
- 74.70M
- Return on equity
- -48.72%
- Short % of float
- 23.76%
- 50-day average
- 3.78
- 200-day average
- 3.48
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 7.32
- Target (high)
- 10.00
- Strong buy2
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.204.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.21 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.21901 | -0.22 | 0.00 | -0.45% |
| Aug 5, 2026 | Jun 30, 2026 | -0.24 | -0.25 | -0.01 | -4.17% |
| May 6, 2026 | Mar 31, 2026 | -0.30 | -0.22 | +0.08 | +26.67% |
| Feb 25, 2026 | Dec 31, 2025 | -0.28 | -0.21 | +0.07 | +25.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.38 | -0.36 | +0.02 | +5.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| May 14, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| May 7, 2026 | Needham | reit | Buy | Buy |
| Apr 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Feb 26, 2026 | B of A Securities | main | Neutral | Neutral |
| Feb 26, 2026 | Needham | reit | Buy | Buy |
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- recursion.com
News
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Break Below 200-Day Moving Average – Should You Sell? 
2 healthcare stocks to turn $10 into $100 by next year 
Recursion to Participate in Upcoming Investor Conferences 
Recursion Appoints Fred Hassan As Board Chair, Effective Oct. 31 
ParaZero Technologies To Provide Earnings Updates And REC-4881 Data As Well As KOL And Patient Panels On Tuesday, November 3, 2026 - Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know 
Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027 
Recursion Commences $200M Common Stock Offering Of 61,540,000 Shares Of Its Class A Common Stock At A Price Of $3.25/Share 
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Your note
Sign in to keep a note on RXRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORGESON BLAKE CHARLES | Director | Sale | Nov 2, 2026 | 6,068,290 |
| DAR ZAVAIN | Director | Stock Award(Grant) | Jun 30, 2026 | 240,764 |
| GIBSON CHRISTOPHER C. | Director | Sale | Jun 4, 2026 | 883,735 |
| HALLETT DAVID | Officer | Stock Award(Grant) | Feb 5, 2026 | 1,109,060 |
| HERSHBERG ROBERT M | Director | Sale | Oct 5, 2026 | 162,156 |
| KHAN NAJAT | Chief Executive Officer | Sale | Sep 7, 2026 | 2,072,890 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.08% | 50,304,691 | 160.22M | Jun 29, 2026 |
| ARK Investment Management, LLC | 6.64% | 41,337,632 | 131.66M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.00% | 31,131,599 | 99.15M | Jun 29, 2026 |
| State Street Corporation | 4.82% | 30,001,137 | 95.55M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.66% | 22,765,940 | 72.51M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 2.92% | 18,174,384 | 57.89M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 3.90% | 24,309,816 | 77.43M | Oct 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.67% | 16,610,690 | 52.91M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.54% | 15,819,431 | 50.38M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.54% | 15,792,915 | 50.30M | Oct 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.14% | 13,319,007 | 42.42M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.83% | 11,420,983 | 36.38M | Jun 29, 2026 |